Work

113P Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)

Year: 2024
Type: article
Study design: Observational Study
Abstract: Patients (pts) with metastatic urothelial carcinoma (mUC) who do not experience disease progression after 4-6 cycles of first-line platinum-based chemotherapy (PBC) may benefit from immunotherapy as maintenance treatment with Avelumab, or receive Pembrolizumab as a second-line.
Language: English
Subfield: Surgery
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405374550
FWCI:
Cites:
Cited by:
Related to: 10